5/7/2013 10:49:10 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ), together with its collaborator, the National Eye Institute (NEI) of the National Institutes of Health (NIH), filed a patent application in the U.S. Patent and Trademark Office on April 26, 2013, directed to immune modulation for the management of autoimmune diseases that may include age-related macular degeneration (AMD), which is a leading cause of blindness in the United States. The product platform is broadly applicable to the management of autoimmune disorders and includes therapeutic compositions and methods of treatment, as well as compositions and methods for diagnostic and prognostic applications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by